STOCK TITAN
  1. Home
  2. Sec-filings
  3. QTEX
  4. [6-K] QTREX Quantum Ltd. Current Report (Foreign Issuer)

QTREX Quantum (QTEX) names AME veteran Dr. Chappel-Ram to board

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

QTREX Quantum Ltd. reports that its Board of Directors appointed Dr. Shlomit Chappel-Ram as an independent director on July 14, 2026, effective immediately. She brings extensive Additively Manufactured Electronics (AME) and multidisciplinary R&D leadership experience, including prior service as Vice President of R&D at Nano Dimension Ltd.

The company recently acquired Nano Dimension’s AME platform in April 2026 and is developing high-density, thermally optimized quantum connectivity solutions and mission‑critical AME applications. QTREX also continues to advance and selectively monetize its medical technology portfolio. The release includes forward-looking statements regarding AME platform advances and Dr. Chappel-Ram’s expected contributions.

Positive

  • None.

Negative

  • None.

Filing Explained

The July 17 Form 6-K furnishes QTREX’s director-appointment release and incorporates specified portions into its existing Form F-3 and Form S-8 registration statements. The structural change is to the registration documents’ incorporated disclosure; the filing does not report that securities were issued or sold.

Appointment date July 14, 2026 Date the Board appointed Dr. Shlomit Chappel-Ram as independent director
Press release date July 17, 2026 Date QTREX Quantum announced the board appointment
Digma Medical GM since January 2025 Start of Dr. Chappel-Ram’s role as General Manager of Digma Medical
Digma VP R&D period start January 2021 Beginning of Dr. Chappel-Ram’s tenure as Vice President R&D at Digma Medical
Digma VP R&D period end December 2024 End of her Vice President R&D role at Digma Medical
Nano Dimension R&D tenure start March 2019 Start of Dr. Chappel-Ram’s work at Nano Dimension Ltd.
Nano Dimension R&D tenure end December 2020 End of her tenure at Nano Dimension Ltd.
Fiscal year referenced December 31, 2025 Fiscal year-end of the Form 20-F risk factor reference
Additively Manufactured Electronics technical
"a company focused on advancing Additively Manufactured Electronics ("AME") for quantum..."
Additively manufactured electronics are electronic components and circuits created by layer-by-layer printing techniques instead of traditional machining or assembly. Think of building a cake where each layer can contain wiring, sensors or conductive traces so a finished part can combine structure and electronics in one piece. For investors, this can cut production time and part counts, enable custom or lightweight designs, and open new product opportunities or cost savings across manufacturing and supply chains.
quantum connectivity technical
"applying it to high-density, thermally optimized quantum connectivity and proprietary..."
Quantum connectivity is the ability to link devices or networks using principles of quantum physics—for example, using entangled particles to share information in ways classical links cannot. For investors, it matters because it promises fundamentally stronger data security and new communication capabilities that could reshape telecom, cloud services and computing markets; like upgrading from a locked mailbox to an unbreakable courier system, it can change the value and risk profile of companies in those sectors.
dilution cryostats technical
"developing high-density, thermally optimized quantum connectivity solutions for dilution cryostats..."
A dilution cryostat is a laboratory machine that creates extremely low temperatures—thousandths of a degree above absolute zero—by using a special mixture of helium isotopes. Think of it as a super-powerful freezer that lets researchers test and run delicate technologies such as quantum processors and ultra-sensitive sensors. For investors, access to or development of these systems signals involvement in advanced, capital-intensive technologies with long development cycles and potential for high strategic value.
mission-critical environments technical
"advancing AME applications for defense, aerospace, missile, space, and other mission-critical..."
Systems, facilities or settings where failure or downtime would cause serious harm to people, operations or finances—such as hospital operating rooms, air-traffic control, or data centers running payment networks. Investors care because equipment reliability, maintenance practices and regulatory approval in these environments directly affect revenue continuity, legal and safety risk, and the value of products or services that must perform without interruption; think of them as the ‘lifesaving gear’ of a business.
forward-looking statements regulatory
"This press release contains express or implied forward-looking statements pursuant to U.S...."
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

FAQ

What board change did QTREX Quantum (QTEX) disclose in this Form 6-K?
QTREX Quantum disclosed that its Board appointed Dr. Shlomit Chappel-Ram as an independent director, effective July 14, 2026. The company highlights her AME and complex hardware scaling experience as aligned with QTREX’s current operational phase and technology roadmap.

What is Dr. Shlomit Chappel-Ram’s background relevant to QTREX Quantum (QTEX)?
Dr. Chappel-Ram previously served as Vice President of R&D at Nano Dimension Ltd., leading multidisciplinary AME teams, and co-authored IEEE research on AME antenna architectures. She also holds a Ph.D. in Chemistry and an MBA from Bar-Ilan University.

How does the new director relate to QTREX Quantum’s (QTEX) AME platform acquisition?
QTREX acquired the AME platform from Nano Dimension in April 2026. Dr. Chappel-Ram helped develop this technology at Nano Dimension, giving the Board direct AME operating experience as QTREX advances high-density quantum connectivity and AME components toward commercial production.

What markets is QTREX Quantum (QTEX) targeting with its AME technology?
QTREX is developing high-density, thermally optimized quantum connectivity for dilution cryostats and advancing AME applications for defense, aerospace, missile, space, and other mission-critical environments. It is also progressing a medical technology portfolio in respiratory support and blood monitoring.

What forward-looking elements are included in QTREX Quantum’s (QTEX) announcement?
The company includes forward-looking statements about AME platform capabilities and advances, the match between Dr. Chappel-Ram’s skills and QTREX’s operational phase, and expectations that she will contribute as the company advances development, qualification and commercial production of its technologies.

Does QTREX Quantum (QTEX) reference any risk disclosures in connection with this update?
Yes. The company notes that more detailed information about its risks and uncertainties appears under “Risk Factors” in its Form 20-F for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of July 2026 (Report No. 3)

 

Commission File Number: 001-40303

 

Qtrex Quantum Ltd.

(Translation of registrant’s name into English)

 

2 Ha-Tidhar St.

Ra’anana 4366504, Israel

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

☒ Form 20-F ☐ Form 40-F

 

 

 

 

 

 

 

CONTENTS

 

On July 17, 2026, Qtrex Quantum Ltd. (the “Company”) issued a press release titled “QTREX Appoints Dr. Shlomit Chappel-Ram, Veteran AME R&D Executive, as Independent Director,” a copy of which is furnished as Exhibit 99.1 with this Report of Foreign Private Issuer on Form 6-K (this “Report”).

 

The first three paragraphs, the fifth paragraph and the section titled “Forward-Looking Statement Disclaimer,” of the press release are incorporated by reference into the Company’s Registration Statements on Form F-3 (Registration Nos. 333-284308, 333-289324 and 333-296482) and Form S-8 (Registration Nos. 333-259057, 333-277980, 333-285565, 333-290162 and 333-292592), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

Exhibit No.    

99.1

   Press release issued by Qtrex Quantum Ltd. on July 17, 2026, titled “QTREX Appoints Dr. Shlomit Chappel-Ram, Veteran AME R&D Executive, as Independent Director.”

 

1

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Qtrex Quantum Ltd.
     
Date: July 17, 2026 By: /s/ Dagi Ben-Noon
    Name: Dagi Ben-Noon
    Title: Chief Executive Officer

 

 

2

 

 

 

Exhibit 99.1 

 

QTREX Appoints Dr. Shlomit Chappel-Ram, Veteran AME R&D Executive, as Independent Director

 

Ness Ziona, Israel, July 17, 2026 – QTREX Quantum Ltd. (Nasdaq: QTEX) (“QTREX” or the “Company”), a company focused on advancing Additively Manufactured Electronics (“AME”) for quantum computing infrastructure, today announced that on July 14, 2026, its Board of Directors (the “Board”) appointed Dr. Shlomit Chappel-Ram as an independent director, effective immediately.

 

Dr. Chappel-Ram previously served as Vice President of R&D at Nano Dimension Ltd. (Nasdaq: NNDM), where she led multidisciplinary teams spanning materials, formulations, chemistry, physics, process engineering, mechanics, software, hardware, and electronics. She also co-authored peer-reviewed IEEE research on AME-fabricated, multi-metal-layer antenna architectures.

 

As previously announced, QTREX acquired the AME platform from Nano Dimension Ltd. in April 2026 and is applying it to high-density, thermally optimized quantum connectivity and proprietary, application-specific RF components. Dr. Chappel-Ram’s appointment adds direct AME operating experience to the Board as QTREX advances its platform from a validated capability into commercial component production.

 

“We are adding to our Board an executive who played a foundational role in developing AME technology and fully recognizes the value it brings to quantum computing infrastructure,” said Dagi Ben-Noon, Chief Executive Officer of QTREX Quantum. “Dr. Chappel-Ram’s deep technical understanding and proven track record in scaling complex hardware directly match the operational phase QTREX is at today.”

 

Dr. Chappel-Ram has served as a General Manager of Digma Medical since January 2025, where she leads operations, product development, regulatory and clinical programs, fundraising, and investor communications. From January 2021 until December 2024 she also served as Digma Medical’s Vice President R&D and was leading Investor Relations activities. She previously held senior R&D roles at Edwards Lifesciences (Cardioband) and Medinol Ltd., alongside her tenure at Nano Dimension Ltd. from March 2019 until December 2020, where she directed complex technology programs from early-stage development through regulatory approval and transfer to manufacturing. Dr. Chappel-Ram serves as a consultant and advisory board of directors’ member at Kidron Capital since April 2021, and also served as a consultant and advisory board of director member at NGLi Holdings from March 2023 until March 2024. Her academic and professional training includes a Ph.D. in Chemistry, summa cum laude, and an MBA from Bar-Ilan University, postdoctoral work in Chemistry and Biochemistry at the City University of New York, and completion of the Directors and Senior Corporate Officeholders Program at Tel Aviv University’s LAHAV Executive Education.

 

“I have seen firsthand what AME can deliver when materials, electrical design and manufacturing are engineered as one integrated system,” said Dr. Chappel-Ram. “QTREX is applying these capabilities to the demanding connectivity requirements of scalable quantum hardware, and I look forward to contributing my experience as the Company advances development, qualification and commercial production.”

 

About QTREX Quantum

 

QTREX Quantum Ltd. (Nasdaq: QTEX) is a technology company focused on advanced connectivity and electronics manufacturing solutions for next-generation hardware markets. Following its acquisition of the AME platform, the Company is developing high-density, thermally optimized quantum connectivity solutions for dilution cryostats and advancing AME applications for defense, aerospace, missile, space, and other mission-critical environments. The Company also continues to advance its medical technology portfolio, including respiratory support and blood monitoring platforms, while actively working to monetize certain parts of the medical business.

 

For more information, please visit: www.q-trex.com

 

Forward-Looking Statement Disclaimer

 

This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the AME platform capabilities and advances; that Dr. Chappel-Ram’s appointment adds direct AME operating experience to the Board; that Dr. Chappel-Ram’s deep technical understanding and proven track record in scaling complex hardware directly match the operational phase QTREX is at today; and the belief that Dr. Chappel-Ram will contribute her experience as the Company advances development, qualification and commercial production . Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements. More detailed information about the risks and uncertainties affecting the Company is contained under “Risk Factors” in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission.

 

Company Contact
QTREX Quantum
Email: info@q-trex.com
Phone: +972-9-9664485

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases